What does the research say about using Treg-targeting strategies for pre-eclampsia safety?
Pre-eclampsia is a serious pregnancy complication linked to immune system problems. Scientists believe that Regulatory T cells (Tregs) help keep the immune system calm during pregnancy. When these cells do not work well, the risk of pre-eclampsia goes up. New treatments that target Tregs are being developed, but they are not yet standard care.
What the research says
A recent review explains that Tregs are vital for maintaining the balance between the mother and the fetus. Problems with these cells, such as low numbers or weak function, are known to increase the risk of pre-eclampsia 2. Because of this link, researchers are looking at ways to fix or boost Treg function to prevent the disease.
However, the same review notes that using these new Treg-targeting therapies in pregnancy is still in its very early stages 2. While these methods are being tested for other conditions like cancer and autoimmune diseases, there is currently no safety data or reported outcomes for pregnant women using them 2.
Other research on pre-eclampsia focuses on different risk factors. For example, high uric acid levels before 20 weeks of pregnancy are linked to a higher risk of pre-eclampsia 1. Similarly, having hidradenitis suppurativa (a skin condition) is associated with a higher chance of developing pre-eclampsia 4. These studies highlight that pre-eclampsia is complex and involves many different body systems, not just the immune cells.
What to ask your doctor
- What are the current standard treatments for pre-eclampsia in my specific case?
- Are there any clinical trials for Treg-targeting therapies that I could join?
- What are the known risks of using new immune therapies during pregnancy?
- How can we monitor my immune health to reduce the risk of pre-eclampsia?
This question is drawn from common patient questions about OB/GYN & Women's Health and answered using cited medical research. We do not provide individualized advice.